Movement Alert｜Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness

Market Focus06-25 10:03

On June 25, Innovent Biologics fell 3.01% in regular trading, trading at 75.35 HKD/share, with turnover of 175 million HKD.

On the news front, the company held its annual general meeting on June 24, where all seven ordinary resolutions passed but encountered unusually high opposition. Notably, the resolution to expand general mandate for share issuance by adding back buyback shares received 48.48% opposition votes. The resolution granting directors general authority to allot and issue additional shares faced 36.68% opposition, while the auditor reappointment resolution saw 22.78% dissent. The high proportion of opposing votes signals significant shareholder discontent with capital management decisions.

Within the Biotechnology sector, the overall sector is under pressure. Among individual stocks, AKESO down 4.0%, REMEGEN down 4.06%, CARSGEN down 7.98%, 3SBIO down 2.13%, BEIGENE down 0.91%, creating broad-based downward momentum that amplified selling pressure on Innovent Biologics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112404157?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112404157","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness","media":"Market Focus","content":"<p><p>On June 25, Innovent Biologics fell 3.01% in regular trading, trading at 75.35 HKD/share, with turnover of 175 million HKD.</p><p>On the news front, the company held its annual general meeting on June 24, where all seven ordinary resolutions passed but encountered unusually high opposition. Notably, the resolution to expand general mandate for share issuance by adding back buyback shares received 48.48% opposition votes. The resolution granting directors general authority to allot and issue additional shares faced 36.68% opposition, while the auditor reappointment resolution saw 22.78% dissent. The high proportion of opposing votes signals significant shareholder discontent with capital management decisions.</p><p>Within the Biotechnology sector, the overall sector is under pressure. Among individual stocks, AKESO down 4.0%, REMEGEN down 4.06%, CARSGEN down 7.98%, 3SBIO down 2.13%, BEIGENE down 0.91%, creating broad-based downward momentum that amplified selling pressure on Innovent Biologics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Innovent Biologics fell 3.01% in regular trading, trading at 75.35 HKD/share, with turnover of 175 million HKD.</p><p>On the news front, the company held its annual general meeting on June 24, where all seven ordinary resolutions passed but encountered unusually high opposition. Notably, the resolution to expand general mandate for share issuance by adding back buyback shares received 48.48% opposition votes. The resolution granting directors general authority to allot and issue additional shares faced 36.68% opposition, while the auditor reappointment resolution saw 22.78% dissent. The high proportion of opposing votes signals significant shareholder discontent with capital management decisions.</p><p>Within the Biotechnology sector, the overall sector is under pressure. Among individual stocks, AKESO down 4.0%, REMEGEN down 4.06%, CARSGEN down 7.98%, 3SBIO down 2.13%, BEIGENE down 0.91%, creating broad-based downward momentum that amplified selling pressure on Innovent Biologics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1112404157","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112404157","pubTimestamp":1782352983,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Innovent Biologics fell 3.01% in regular trading, trading at 75.35 HKD/share, with turnover of 175 million HKD.On the news front, the company held its annual general meeting on June 24,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静快讯|信达生物常规交易跌3.01%板块疲软下股东大会决议遭高调反对","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 25, Innovent Biologics fell 3.01% in regular trading, trading at 75.35 HKD/share, with turnover of 175 million HKD.On the news front, the company held its annual general meeting on June 24, where all seven ordinary resolutions passed but encountered unusually high opposition. Notably, the resolution to expand general mandate for share issuance by adding back buyback shares received 48.48% opposition votes. The resolution granting directors general authority to allot and issue additional shares faced 36.68% opposition, while the auditor reappointment resolution saw 22.78% dissent. The high proportion of opposing votes signals significant shareholder discontent with capital management decisions.Within the Biotechnology sector, the overall sector is under pressure. Among individual stocks, AKESO down 4.0%, REMEGEN down 4.06%, CARSGEN down 7.98%, 3SBIO down 2.13%, BEIGENE down 0.91%, creating broad-based downward momentum that amplified selling pressure on Innovent Biologics.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112404157","isCrawlerRequest":true}